Evidence map›Paper›PMID 39245547›Full record

ReviewInterventional cardiology clinics2024

Genetic Determinants of Response to P2Y

Larisa H Cavallari, James C Coons

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Interventional cardiology clinics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Larisa H CavallariDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Precision Medicine, University of Florida, 1333 Center Drive, PO Box 100486, Gainesville, FL 32610, USA. Electronic address: lcavallari@cop.ufl.edu.
James C CoonsDepartment of Pharmacy and Therapeutics, Center for Clinical Pharmaceutical Sciences, University of Pittsburgh, 9058 Salk Hall, 3501 Terrace Street, Pittsburgh, PA 15261, USA.

Funding

Precision antiplatelet therapy after percutaneous coronary interventionR01HL149752 · NHLBI · UNIVERSITY OF FLORIDA · PI CAVALLARI, LARISA HUMMA, LEE, CRAIG R · 2020 to 2024
$3.5M
NHLBI NIH HHS R01 HL149752
6 · The paper itself

Abstract

The CYP2C19 enzyme metabolizes clopidogrel, a prodrug, to its active form. Approximately 30% of individuals inherit a loss-of-function (LoF) polymorphism in the CYP2C19 gene, leading to reduced formation of the active clopidogrel metabolite. Reduced clopidogrel effectiveness has been well documented in patients with an LoF allele following an acute coronary syndrome or percutaneous coronary intervention. Prasugrel or ticagrelor is recommended in those with an LoF allele as neither is affected by CYP2C19 genotype. Although data demonstrate improved outcomes with a CYP2C19-guided approach to P2Y

Indexed as

Cytochrome P-450 CYP2C19Purinergic P2Y Receptor AntagonistsAcute Coronary SyndromeClopidogrelGenotypeHumansPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPolymorphism, GeneticPrasugrel HydrochlorideTicagrelorClopidogrelCYP2C19 protein, humanCytochrome P-450 CYP2C19Platelet Aggregation InhibitorsPrasugrel HydrochloridePurinergic P2Y Receptor AntagonistsTicagrelorClopidogrelCYP2C19GenotypePharmacogenomicsPrasugrelTicagrelor

Identifiers

PMID39245547
PMCPMC11483879

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.